Edwards Lifesciences' Q4 Earnings on Deck: Here's What to Expect

Key Takeaways EW is set to report Q4 2025 results on Feb. 10, with revenues expected to rise 11.1% year over year. EW's TAVR segment is expected to benefit from global procedure growth and higher sales guidance for 2025. EW's TMTT arm is projected to post 44.2% sales growth, aided by traction in PASCAL, EVOQUE and SAPIEN M3.Edwards Lifesciences Corp. (EW) is scheduled to report fourth-quarter 2025 results on Feb. 10, after market close.In the last reported quarter, the company’s adjusted earnings per share ...